Gynecologic Cancers
See who the oncology community selected as the rising stars of 2026!
We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.
At ESGO26 investigators answered some of the field’s most persistent questions: the optimal timing of surgery, chemotherapy scheduling, the promise of immunotherapy in platinum-resistant disease and how molecular profiling can sharpen surgical decision-making. And the results didn't disappoint. Below are four of the most important abstracts from the Late-breaking, Best Oral and Best Three Minutes sessions: ENGOT-ov65/KEYNOTE-B96, RACC, ACR-368-201 and EUGENIE revealed insights that could shift the standard of care. Here’s what you need to know.
At ESGO26, investigators tackled some of the most persistent questions in advanced ovarian cancer: when to operate, how best to schedule chemotherapy and whether immunotherapy can finally shift outcomes in platinum-resistant disease. Four major studies took centre stage — TRUST, ICON8B, ENGOT-ov65/KEYNOTE-B96 and a SUROVA HIPEC sub-analysis. Here, we break down the key take-home messages from each presentation.
February has already been very busy across regulation, clinical research and community awareness - and we're only half way through! See below a round-up of the main breakthroughs and what to look out for during the rest of the month. ...
The European Society for Medical Oncology (ESMO) 2025 congress brought over 100 late-breaking abstracts, 250 sessions, 600 expert speakers and 33,800 delegates to Berlin in October. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of oncology practice.
The European Society for Medical Oncology (ESMO) 2025 congress brought over 100 late-breaking abstracts, 250 sessions, 600 expert speakers and 33,800 delegates to Berlin in October. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of oncology practice.
In this interview, we speak with Prof. Domenica Lorusso (Humanitas Hospital San Pio X, Humanitas University, Rozzano, Milan) about the latest ROSELLA findings, their implications for clinical practice, the next steps in this research and other key data presented at this year’s meeting.
At the ESMO Annual Meeting 2025, Dr Antonio González-MartÃn unveiled pivotal data from the ANITA and NAPISTAR-101 trials, spotlighting new insights into immunotherapy, biomarkers and new antibody–drug conjugates for recurrent and platinum-resistant ovarian cancer.
It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This edition showcases the continued advances and innovation reshaping cancer care, as well as highlighting the continued unmet needs and challenges associated with ...
At the 2025 European oncology congress, Prof. Nicoletta Colombo highlighted data from the ENGOT-ov65/KEYNOTE-B96 study showing pembrolizumab plus weekly paclitaxel, with or without bevacizumab, significantly improved survival in platinum-resistant ovarian cancer. The findings suggest this combination could establish a new standard of care, addressing a long-standing unmet clinical need.
In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted rest impacts physician health in both the short and long term, safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
Cervical cancer (CC) is the fourth most common cancer among women worldwide, with an estimated 604,000 new cases and 342,000 CC-related deaths in 2020.1# Approximately 90% of CCs are caused by infection with human papillomavirus (HPV).2Â Even though the adoption of both primary (HPV ...
Rare gynaecological cancers remain an underfunded and understudied group of diseases. Prof. Isabelle Ray-Coquard discusses the diagnostic and therapeutic gaps, barriers to clinical trial participation, and the importance of international cooperation to advance care for these patients. Promising developments include immunotherapy, targeted approaches, and data-driven personalized strategies.
Dr Domenica Lorusso reviews key ovarian cancer studies from ASCO 2025, including new data on immunotherapy combinations, survival benefit in platinum-resistant disease, and surgical outcomes in newly diagnosed patients. While not practice-changing, the results add to the evidence base and may guide more tailored decision-making in clinical practice.
At ASCO 2025, cervical cancer took centre stage in gynecologic oncology with data showing how immunotherapy is redefining the treatment landscape. Trials such as KEYNOTE-826 and KEYNOTE-A18 demonstrated meaningful gains in survival, while emerging antibody–drug conjugates point to a new wave of personalised therapy for this historically underserved disease.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
